Table 3.
Prospective associations of FLI with incident type 2 diabetes.
| Non-Elevated FLI (<60) | Elevated FLI (≥60) | ||
| Participants, n | 4120 | 1671 | |
| Incident T2D, n (%) | 82 (2.0) | 194 (11.6) | |
| HR (95% CI) | p -Value | ||
| Crude Model | (ref) | 6.78 (5.23–8.79) | <0.001 |
| Model 1 | (ref) | 5.84 (4.46–7.66) | <0.001 |
| Model 2 | (ref) | 5.72 (4.37–7.50) | <0.001 |
| Model 3 | (ref) | 5.64 (4.31–7.39) | <0.001 |
| Model 4 | (ref) | 5.09 (3.77–6.88) | <0.001 |
| Model 5 | (ref) | 3.84 (2.76–5.36) | <0.001 |
| Model 6 | (ref) | 3.46 (2.45–4.87) | <0.001 |
Data are presented as hazard ratio (HR) with 95% confidence interval (CI). FLI, fatty liver index; BCAA, branched-chain amino acids; T2D, type 2 diabetes. Model 1: adjusted for age and sex. Model 2: adjusted for age, sex and family history of type 2 diabetes. Model 3: adjusted for age, sex, family history of type 2 diabetes, alcohol intake and current smoking. Model 4: adjusted for age, sex, family history of type 2 diabetes, alcohol intake, current smoking, eGFR, UAE, antihypertensive medication and lipid-lowering drugs. Model 5: adjusted for age, sex, family history of type 2 diabetes, alcohol intake, current smoking, eGFR, UAE, antihypertensive medication, lipid-lowering drugs, HOMA-IR and HOMA-β. Model 6: adjusted for age, sex, family history of type 2 diabetes, alcohol intake, current smoking, eGFR, UAE, antihypertensive medication, lipid-lowering drugs, HOMA-IR, HOMA-β and BCAAs.